T
Thomas Gauler
Researcher at University of Duisburg-Essen
Publications - 175
Citations - 9769
Thomas Gauler is an academic researcher from University of Duisburg-Essen. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 34, co-authored 157 publications receiving 8199 citations. Previous affiliations of Thomas Gauler include The Royal Marsden NHS Foundation Trust & University of Düsseldorf.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.
Journal ArticleDOI
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal Machiels,Robert I. Haddad,Jérôme Fayette,Lisa Licitra,Makoto Tahara,Jan B. Vermorken,Paul Clement,Thomas Gauler,Didier Cupissol,Juan J. Grau,Joël Guigay,F. Caponigro,Gilberto de Castro,Luciano de Souza Viana,Ulrich Keilholz,Joseph M. del Campo,X.J. Cong,E. Ehrnrooth,Ezra E.W. Cohen +18 more
TL;DR: Afatinib was associated with significant improvements in progression-free survival and had a manageable safety profile and support further investigations with irreversible ERBB family blockers in HNSCC.
Journal ArticleDOI
Systemic therapy in metastatic renal cell carcinoma
Jens Bedke,Thomas Gauler,Viktor Grünwald,Axel Hegele,Edwin Herrmann,Stefan Hinz,Jan Janssen,Stephan Schmitz,Martin Schostak,Hans Tesch,Stefan Zastrow,Kurt Miller +11 more
TL;DR: Despite the high level of evidence for first and second-line treatment in mRCC, data for third-line therapy are limited and possible sequences include TKI-mTOR-TKI or TKI–TKI- mTOR with the upcoming checkpoint inhibitors in perspective, which might settle a new standard of care after previous TKI therapy.
Journal ArticleDOI
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.
Christoph Pöttgen,Sabine Levegrün,Dirk Theegarten,Simone Marnitz,Sara Grehl,Roman Pink,Wilfried Eberhardt,Georgios Stamatis,Thomas Gauler,Gerald Antoch,Andreas Bockisch,Martin Stuschke +11 more
TL;DR: Values from two serial PET/CT scans, before and after three chemotherapy cycles or later, allow prediction of histopathologic response in the primary tumor and mediastinal lymph nodes and have prognostic value.